Business Of Biotech Manufacturing Partnership With Life Biosciences' Jerry McLaughlin and Forge Biologics' John Maslowski
7 snips
Dec 9, 2024 Jerry McLaughlin, CEO of Life Biosciences, and John Maslowski, newly appointed CEO of Forge Biologics, delve into groundbreaking topics in biotech. They discuss advancements in partial epigenetic reprogramming therapies and their collaboration on clinical trials. The conversation also highlights strategic growth and leadership changes at Forge after its acquisition. Insights into the thriving biotech environment in Columbus are shared, emphasizing the importance of trust and communication in successful partnerships within the sector.
AI Snips
Chapters
Transcript
Episode notes
Life Biosciences Progress
- Life Biosciences is preparing for a 2025 IND for a partial epigenetic reprogramming therapy.
- They've replicated successful non-human primate studies and received recognition as a top biotech company.
CDMO Selection Criteria
- When choosing a CDMO, prioritize team expertise, commitment, and eagerness to succeed.
- Vet their history and ensure they prioritize your program.
CDMO Vetting Process
- Life Biosciences narrowed their CDMO search from 12 to 3 through rigorous vetting.
- They used outside consultants and conducted site visits to evaluate technical expertise and cultural fit.